Written questions by Gordon.

When the 10-Year NHS Workforce Plan will be published.

We will publish the 10 Year Workforce Plan in spring 2026.

Whether in person support will also be provided where necessary in addition to the digital first prehabilitation offer for people with cancer set out in the National Cancer Plan.

The National Cancer Plan sets out that we will deliver new quality standards for prehabilitation across the country in 2028 to help patients get healthier before treatment. The new standards will ensure access to prehabilitation services and that they fit around patients’ lives. This will include in person support where that is more appropriate for the patient and bringing services into the community and closer to patients’ homes.Part of that will include the roll out a national digital first prehabilitation offer through the NHS App and other digital channels. This will help support patients closer to home, where that is their preference.

Whether the 10 Year NHS Workforce Plan will include measures to (a) increase the clinical academic workforce and (b) ensure that all regions have access to a strong clinical academic base.

The Government is committed to publishing a 10 Year Workforce Plan to set out action to create a workforce ready to deliver the transformed service set out in the 10-Year Health Plan. The 10 Year Workforce Plan will ensure the National Health Service has the right people in the right places, with the right skills to care for patients, when they need it. We are working through how the plan will articulate the changes for different professional groups.The Department, through the National Institute for Health and Care Research (NIHR), is the United Kingdom’s largest funder of clinical academic training. The NIHR delivers a comprehensive research career pathway, from internships and predoctoral fellowships through to research professorships, for the full range of clinicians working across England, providing the skilled research workforce in universities and NHS trusts to lead research and help train future generations of clinicians. The NIHR invests over £220 million each year in research training programmes.

If he will make it policy to extend funding for Type 1 Diabetes and Disordered Eating pilot programmes to ensure (a) they do not collapse and (b) a national network of specialist treatment centres can be established.

Funding for the Type 1 Diabetes and Disordered Eating (T1DE) pilots was time-limited with the expectation that once the national funding expires, responsibility for considering the future provision of T1DE services would sit with the relevant integrated care board (ICB) who are responsible for planning and commissioning diabetes treatment and care.NHS England has previously extended the initial two-year funding term, which has enabled the sites to run for much longer than initially expected. NHS England is providing evaluation data to the ICBs to support local decision making. The pilot sites will receive confirmation in relation to any future national funding shortly.

With reference to the 2024 National NHS Staff Survey Results, if he will publish data on staff wellbeing indicators for (a) clinical radiology and (b) clinical oncology, including the data by specialty for (i) q10b on additional paid hours worked, (ii) q10c on additional unpaid hours worked, (iii) q11c on work related stress and (iv) q12b on burnout.

The Department does not hold this data nor are there any plans to collect NHS Staff Survey data from any additional occupational groups.As reported in the 2024 NHS Staff Survey, 30.24% of respondents reported having felt burnout because of their work. Data taken from the NHS Staff Survey cannot however be used to identity trends in specialities.

With reference to the 2024 National NHS Staff Survey Results, what data his Department holds on whether (a) consultants, (b) trainees and (c) specialty, associate specialists and specialist doctors in (i) clinical radiology and (ii) clinical oncology believe there are enough staff in their organisation for them to do their job properly.

The Department does not hold this data. As reported in the 2024 NHS Staff Survey, 34.01% of respondents said that there are enough staff at their organisation for them to do their job properly. The data from the Staff Survey cannot, however, be used to identity trends in specialities.

With reference to the 2024 National NHS Staff Survey Results, what data his Department holds on staff wellbeing indicators for (a) consultants, (b) trainees and (c) specialty, associate specialists and specialist doctors in (i) clinical radiology and (ii) clinical oncology, including (A) additional paid hours worked, (B) additional unpaid hours worked, (C) trends in the level of stress and (D) trends in the level of burnout.

As reported in the 2024 NHS Staff Survey, 30.24% of respondents reported having felt burnout because of their work. Data taken from the NHS Staff Survey cannot however be used to identity trends in specialities.

What steps his Department are taking to improve procedures for processing gestational diabetes blood glucose tests to improve the accuracy of diagnosis.

The National Institute for Health and Care Excellence is responsible for setting clinical guidelines. For diabetes in pregnancy, including testing for gestational diabetes, the relevant clinical guideline is NG3 - Diabetes in pregnancy: management from preconception to the postnatal period, which is available at the following link:https://www.nice.org.uk/guidance/ng3/chapter/Recommendations#gestational-diabetesThe Department provides funding to the National Institute for Health and Care Research for research to help improve procedures around gestational diabetes, such as the DOMINO study, with further information available at the following link:https://fundingawards.nihr.ac.uk/award/NIHR134628

What steps he is taking to ensure the NHS lung cancer screening programme receives sufficient funding to ensure its completion by 2029.

The National Health Service will build on its recent successes, including roll-out of the National Lung Cancer Screening Programme, to diagnose cancer earlier and boost survival rates. Funding for national lung screening is set by NHS England and the timescale for full implementation of the National Lung Cancer Screening Programme will be specified in due course.The NHS is currently rolling out the National Lung Cancer Screening Programme to people with a history of smoking. The public health functions agreement between NHS England and the Department sets out that the Lung Cancer Screening Programme has a target to invite 50% of the eligible population by the end of March 2026.

What assessment he has made of the potential merits of including (a) prehabilitation and (b) rehabilitation as essential elements of cancer treatment.

The Department and NHS England are taking a number of steps to support the National Health Service to deliver cost-effective prehabilitation and rehabilitation services.NHS England has highlighted the positive impact of efficient prehabilitation and rehabilitation on cancer outcomes and the potential to lead to cost savings. The ‘PRosPer’ cancer prehabilitation and rehabilitation learning programme, launched as a partnership between NHS England and Macmillan Cancer Support, aims to support allied health professionals and the wider healthcare workforce in developing their skills in providing prehabilitation and rehabilitation as essential elements of cancer treatment.The National Cancer Plan, to be published later this year, will look at how to improve patient outcomes across the entirety of the cancer pathway, from referral and diagnosis to treatment and ongoing care, including prehabilitation and rehabilitation services where appropriate.

What consideration he has given to supporting the National Screening Committee to (a) more swiftly implement innovation within screening programmes and (b) adopt innovative new programmes once proven effective.

The UK National Screening Committee (UK NSC) and its secretariat have adopted several robust strategies that support responsiveness to innovation in screening.The committee uses the expertise of its research and methodology group to help researchers focus the design of screening research to ensure it addresses questions in a way that is useful for screening policy. Where screening research trials are ongoing, the secretariat maintains close contact with researchers to ensure that we are proactive in response to the results coming out of the trial.Where there are evidence gaps in screening research, in-service evaluations provide an innovative solution to generating high quality evidence for the UK NSC in live National Health Services. The UK NSC secretariat works closely with NHS England on upcoming work so that the NHS can optimise their preparations in their readiness for the implementation of recommendations agreed by ministers.Networking across the healthcare landscape both nationally and internationally helps to ensure that the UK NSC keeps abreast of developments in screening and identifies viable innovations in tests and treatments that are suitable in the context of the United Kingdom. Collaboration between organisations such as the National Institute for Health and Care Research, the National Institute for Health and Care Excellence, the Scottish Intercollegiate Guidelines Network, and professional bodies such as the Royal College of Obstetricians and Gynaecologists supports joined up working with partners and avoids unnecessary duplication.

What steps his Department is taking to ensure that the National Institute for Health and Care Excellence (a) review and (b) update clinical guidelines on (i) diagnosis and (ii) treatment of type 1 diabetes and eating disorders.

The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for determining whether its guidelines should be reviewed or updated in light of new evidence. NICE takes a proactive approach to surveillance, monitoring for changes in the evidence base that may impact on its recommendations. Topics for new or updated guidance are considered through the NICE prioritisation process. Decisions as to whether NICE will create new, or update existing, guidance are overseen by a prioritisation board, chaired by NICE’s Chief Medical Officer.NICE intends to carry out focussed updates to all diabetes guidance to take account of changes in insulin availability, but has no current plans for further updates to its guidelines on type 1 diabetes or eating disorders.

Whether Integrated Care Boards will be required to provide sustainable funding for successful pilot projects on Type 1 Diabetes and Eating Disorders to become regional centres of excellence.

NHS England has provided up to £1.5 million a year for the five current Type 1 Disordered Eating pilots for three years. This funding is transferred to integrated care boards on an annual basis and in 2025/26 has been ringfenced.Decisions on funding for future years have yet to be taken.

What steps he is taking to raise awareness of Type 1 Diabetes and Eating Disorders among healthcare professionals in (a) diabetes and (b) eating disorder services.

NHS England is currently funding five Type 1 Disordered Eating (T1DE) Pilots, with the aim of increasing understanding of the characteristics and care needs of people with T1DE, assessing the feasibility of the service delivery model and build the evidence base for an integrated diabetes and mental health pathway. Pilot sites are delivering a national high level service specification alongside testing local novel approaches to improving care including to awareness raising of the condition amongst both diabetes and eating disorder health care professionals.A national evaluation is currently underway to assess the impact of the five current pilot services. NHS England will review the evaluation findings to understand further opportunities to promote awareness of Type 1 disordered eating amongst healthcare professionals.NHS England works alongside its partners to support the delivery of key messages around diabetes education and awareness. This includes through a digital diabetes platform which is developing educational resources for T1DE.

Whether he has conducted an impact assessment of the effect of the abolition of Healthwatch on (a) patient representation, (b) accountability and (c) local authority scrutiny functions.

The abolition of Healthwatch England, the transfer of its functions and the changes to local Healthwatch require primary legislation. Timing of this is subject to the will of parliament and will happen when parliamentary time allows. A full impact assessment would be produced in line with HM Treasury's Green Book standards and published on the Government website when legislation is introduced in Parliament. No assessment has been made at this time, although the expertise of Dr Dash and her critical review of patient safiety will continue to guide the Government’s policy in this regard.

What steps he will take to ensure that (a) the views of patients and (b) patient engagement are independently provided to (a) his Department, (b) the NHS, and (c) local authorities after Healthwatch's abolition.

Dr Dash’s review of patient safety across the health and care landscape was published in July 2025. The review recommends bringing together the work of local Healthwatch organisations, and the engagement functions of integrated care boards and providers, to ensure patient and wider community input into the planning and design of services.In addition, as also recommended by the review, we are amalgamating the functions of Healthwatch England to a new directorate. Its strategic functions will be transferred to the new directorate for patient experience in NHS England, transferring, in due course, to the new structures in the Department. This directorate will be responsible for overseeing the collection of more informed feedback from both patients, service users and carers and significantly improving the complaints function across the National Health Service.These changes will improve quality, including safety, by making it clear where responsibility and accountability sit at all levels of the system, and making it easier for staff, patients and users to directly feed into the system to improve quality of care. We believe that patients and users will have a stronger voice once it is heard inside the system.

Whether his Department will ringfence funding for independent patient advocacy services after the abolition of Healthwatch.

The independent complaints advocacy service in the National Health Service is covered by a wider grant for Local Reform and Community Voices and is not a requirement of Healthwatch England or Local Healthwatch. This grant provides funding to local authorities which assists them in meeting statutory duties. This funding will continue to be provided. This grant has not been ringfenced to date and there are no plans to ringfence it, moving forward.

What assessment he has made of the potential merits of extending the provision of Covid vaccinations to people with (a) type 1 diabetes and (b) long term immunosuppressive health conditions.

The Joint Committee on Vaccination and Immunisation (JCVI) is an independent expert committee which reviews the latest data on COVID-19 risks, vaccine safety, and effectiveness and advises the government on eligibility for vaccination and immunisation programmes. The JCVI has published advice for future COVID-19 vaccination campaigns in autumn 2025, spring 2026, autumn 2026, and spring 2027. The government has accepted JCVI advice for autumn 2025. The Government is considering the JCVI’s advice for 2026 and spring 2027 carefully and will respond in due course.The primary aim of the national COVID-19 vaccination programme remains the prevention of serious disease (hospitalisations and deaths) arising from COVID-19. The JCVI assessment indicates that the oldest age cohorts and individuals who are immunosuppressed are the two groups who continue to be at higher risk of serious disease.Therefore, in autumn 2025, a COVID-19 vaccination will be offered to:adults aged 75 years and over;residents in a care home for older adults;individuals aged 6 months and over who are immunosuppressed (as defined in the ‘immunosuppression’ sections of tables 3 or 4 in the COVID-19 chapter of the UK Health Security Agency Green Book).The JCVI has advised that more recent data are needed to assess whether any other population groups under the age of 75 years with specific clinical comorbidities, such as type 1 diabetes, are at similar risk of serious disease as those aged 75 years and over.The JCVI continues to review evidence and may update its advice in future.

What steps he is taking to improve the quality of national primary care data on Young Onset Dementia.

Young onset dementia is defined as dementia diagnosed under the age of 65.The dementia diagnosis rate is not calculated for patients aged under 65 years old. This is because the numbers of patients known to have dementia in the sample population age groups comprising those aged between zero and 64 years old are not large enough for reliable estimates to be made.The dementia diagnosis rate for patients aged 65 years old and over is calculated and published monthly via the Primary Care Dementia Data publication, which is available at the following link: https://digital.nhs.uk/data-and-information/publications/statistical/primary-care-dementia-dataThis publication does include a monthly count of the number of patients aged 65 years old and under who do have a dementia diagnosis on their patient record. This is expressed as a raw count and as a percentage of registered patients aged between zero and 64 years old.

What assessment his Department has made of the potential merits of having a universal screening programme for type 1 diabetes.

I refer the Hon. Member to the answer I gave to the Hon. Member for South Northamptonshire on 25 July 2025 to Question 67791.